Working with Academia, Industry, Regulators and Patients

Czechia has a strong tradition of close collaboration across the entire innovation ecosystem, connecting academia, industry, regulators, and patients in the shared goal of advancing precision and personalised health. Academic institutions and university hospitals serve both as key contributors and active users of the EATRIS CZ infrastructure. They access its platforms to develop biomarkers, novel diagnostics, and advanced therapies, benefiting from expertise in regulatory science, data management, and clinical translation.

EATRIS CZ researchers also work hand in hand with industry partners, from spin-offs and SMEs to multinational pharmaceutical and biotechnology companies such as Zentiva, Swiss Rockets, Interpharma Praha, BioVendor, Roche, AstraZeneca, Illumina, BGI, Rovers, and others. These collaborations drive the co-development of innovative diagnostics, therapeutics, and patient-friendly self-sampling and monitoring kits.

At the same time, EATRIS CZ maintains continuous dialogue with regulators, including the State Institute for Drug Control (SÚKL), ICT Zlín (as a notified body), and European authorities, ensuring that new medical products and technologies comply with IVDR and the European Medicines Agency standards.

Additionally, patients and patient organisations are increasingly engaged as co-creators and users, helping to identify unmet needs, shape research priorities, and validate new tools designed for real-world healthcare. This integrated approach, linking academia, industry, regulators, and patients, accelerates the path from discovery to clinical impact and ensures that innovation in Czechia remains both scientifically robust and centred on patient benefit.

EATRIS Czech Republic in the Spotlight Programme

In 2025, the Czech Republic was selected as the fourth country, after Spain, Sweden and Portugal, to participate in the EATRIS Spotlight Programme – an initiative designed to showcase national excellence and capabilities in translational medicine across Europe.

The coordination of EATRIS CZ, led by the Institute of Molecular and Translational Medicine (IMTM) at Palacký University Olomouc, launched preparations for the national programme during the annual EATRIS CZ meeting earlier this year. Through a collaborative process involving universities, hospitals, and research institutes, the overarching theme of the Czech Spotlight was defined as: “Precision and Personalized Health – from Discovery to Patient.”

Member institutions were invited to propose events such as workshops, symposia, and public engagement activities covering the topic and including presentations from Czech and international EATRIS institutes. The Czech Spotlight Programme highlights the country’s contribution to building a future where healthcare is more precise, predictive, and patient-centred. By fostering strong connections between science, industry, regulation, and society, Czechia is not only advancing medical innovation at home but also strengthening Europe’s strategic autonomy in health.

Czech Spotlight on Precision and Personalized Health will showcase pioneering projects, infrastructures, and partnerships that embody this vision – from biomarker-driven cancer therapies to AI-powered digital twins for healthy ageing – and will highlight how Czech science contributes to a healthier future for all Europeans. All Spotlight events will be open to the entire EATRIS community and the wider public, and we warmly welcome participation. Registration details and the full event calendar will be available on the EATRIS CZ website.